The S&P 500 is almost exactly where it was one year ago. But fortunately, it took a bumpy path to get back to this point. Corrections in August and January, and milder but significant selloffs in September, November and February, created ample buying opportunities for attractive stocks — and we were happy to take advantage. Let’s take a look at some of our winners to see whether they remain worthwhile buy candidates, or if holding or taking profits makes more sense. #-ad_banner-#Arotech (Nasdaq: ARTX) is up about 50% since I recommended it on Dec. 17. The specialty defense contractor makes… Read More
The S&P 500 is almost exactly where it was one year ago. But fortunately, it took a bumpy path to get back to this point. Corrections in August and January, and milder but significant selloffs in September, November and February, created ample buying opportunities for attractive stocks — and we were happy to take advantage. Let’s take a look at some of our winners to see whether they remain worthwhile buy candidates, or if holding or taking profits makes more sense. #-ad_banner-#Arotech (Nasdaq: ARTX) is up about 50% since I recommended it on Dec. 17. The specialty defense contractor makes simulators, trainers and high-performance batteries for aviation and marine use. Its customers include U.S. and foreign military and homeland security forces. As I wrote in December, the U.S. defense budget is on the rise, thanks to a rare bipartisan agreement between Congress and the White House that loosened the purse strings after a few years of austerity. Arotech’s innovative products are on the shopping lists of every military procurement strategist, as they provide next-generation capabilities of use in modern conflicts. For example, Arotech is the supplier for the U.S. Army’s SWIPES program (Soldier Worn Integrated Power Equipment Systems), which give… Read More